GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-448-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$52.52 million
Profitability
Miscellaneous
Employees517
OptionableOptionable
GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc (NASDAQ:GNMK) posted its earnings results on Monday, October, 29th. The medical equipment provider reported ($0.20) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.20). The medical equipment provider earned $15.80 million during the quarter, compared to analysts' expectations of $15.76 million. GenMark Diagnostics had a negative return on equity of 95.36% and a negative net margin of 79.33%. View GenMark Diagnostics' Earnings History.
When is GenMark Diagnostics' next earnings date?
What price target have analysts set for GNMK?
5 brokerages have issued 12 month price targets for GenMark Diagnostics' shares. Their predictions range from $7.00 to $11.00. On average, they anticipate GenMark Diagnostics' stock price to reach $9.50 in the next year. This suggests a possible upside of 41.2% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.
What is the consensus analysts' recommendation for GenMark Diagnostics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics.
Has GenMark Diagnostics been receiving favorable news coverage?
Media stories about GNMK stock have trended neutral recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Tactile Systems Technology (TCMD), AtriCure (ATRC), Orthofix Medical (OFIX), K2M Group (KTWO), Cardiovascular Systems (CSII), Luminex (LMNX), Intersect ENT (XENT), Cryolife (CRY), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Antares Pharma (ATRS) and LeMaitre Vascular (LMAT).
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- Mr. Hany Massarany, CEO, Pres & Director (Age 58)
- Mr. Scott Mendel, Chief Financial Officer (Age 52)
- Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
- Mr. Brian Andrew Mitchell, Sr. VP of Operations (Age 54)
- Mr. Johnny Ek, VP of Fin. & Accounting and Corp. Controller
Who are GenMark Diagnostics' major shareholders?
GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Casdin Capital LLC (6.82%), BlackRock Inc. (6.50%), Bellevue Group AG (3.57%), Bank of America Corp DE (2.15%), Penn Capital Management Co. Inc. (1.43%) and Northern Trust Corp (1.23%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.
Which major investors are selling GenMark Diagnostics stock?
GNMK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Thrivent Financial for Lutherans, TD Asset Management Inc., Donaldson Capital Management LLC, MetLife Investment Advisors LLC, Royce & Associates LP, Two Sigma Advisers LP and Stephens Inc. AR. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.
Which major investors are buying GenMark Diagnostics stock?
GNMK stock was bought by a variety of institutional investors in the last quarter, including Bellevue Group AG, Assenagon Asset Management S.A., Penn Capital Management Co. Inc., Casdin Capital LLC, Bank of America Corp DE, Rhumbline Advisers, Geode Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for GenMark Diagnostics.
How do I buy shares of GenMark Diagnostics?
Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GNMK stock can currently be purchased for approximately $6.73.
How big of a company is GenMark Diagnostics?
GenMark Diagnostics has a market capitalization of $376.58 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.
What is GenMark Diagnostics' official website?
How can I contact GenMark Diagnostics?
GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]
MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
